{"id":"W135063420","doi":"10.1182/blood.v124.21.529.529","title":"First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Medicine; Hypomethylating agent; Pharmacodynamics; Internal medicine; Adverse effect; Myelodysplastic syndromes; Phases of clinical research; Neutropenia; Pharmacokinetics; Clinical trial; Gastroenterology; Azacitidine; Febrile neutropenia; Oncology; Bone marrow; Chemotherapy; DNA methylation; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001762918,0.001743423,0.001965878,0.000275059,0.0004154807,0.000782728,0.0006255485,0.001195367,0.005187896],"category_scores_gemma":[0.001147203,0.0007006864,0.0009967183,0.0002624247,0.00112936,0.0007837203,0.000330097,0.003219631,0.0009774272],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008633355,"about_ca_system_score_gemma":0.0009636162,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005286187,"about_ca_topic_score_gemma":0.001213193,"domain_scores_codex":[0.9994832,0.0002599081,0.00002893299,0.0001050546,0.00004759387,0.00007522925],"domain_scores_gemma":[0.9992064,0.000170844,0.0001300592,0.00009172528,0.00005170295,0.0003492778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7774366,0.08671595,0.005667042,0.0004950533,0.0008855007,0.0001904057,0.0002913181,0.00179329,0.0634146,0.0002175933,0.003177366,0.05971525],"study_design_scores_gemma":[0.5801263,0.4058984,0.007271183,0.00001330259,0.0002723683,0.0001351789,0.00002515249,0.0007357545,0.003748682,0.0001273419,0.001622943,0.00002331971],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922746,0.000861204,0.0007042768,0.0003250937,0.0001225043,0.003029535,0.001092906,0.00009962844,0.001490156],"genre_scores_gemma":[0.9858964,0.0007329945,0.002297021,0.0009566361,0.0001993146,0.003675023,0.002812963,0.00003937322,0.003390271],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005187896,"threshold_uncertainty_score":0.01735526,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02852010150633002,"score_gpt":0.3203481299052177,"score_spread":0.2918280283988877,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}